CalciMedica Announces Private Placement of up to Approximately $55 Million

Rhea-AI Summary

CalciMedica, Inc. announced a securities purchase agreement to raise up to $55 million in gross proceeds, with an upfront funding of $20.4 million and potential additional funding of $34.2 million. The financing will support the expansion of Auxora™ clinical development, including planned Phase 2 acute kidney injury (AKI) trial, and fund subsequent clinical trials in acute pancreatitis (AP) and AKI programs. New and existing investors, including healthcare-dedicated investors, are participating in the financing.

Financial Analyst

The upfront financing of $20.4 million obtained by CalciMedica, with the potential for an additional $34.2 million, represents a significant capital infusion for the company. This funding is earmarked for the expansion of clinical trials for Auxora™, particularly a Phase 2 acute kidney injury (AKI) trial. The availability of these funds is crucial as it provides the financial runway needed to reach potentially pivotal trials in the company's acute pancreatitis (AP) and AKI programs.

From an investment perspective, the participation of notable healthcare-dedicated investors like Deerfield Management and Aisling Capital, among others, can be seen as a vote of confidence in CalciMedica's pipeline and strategic direction. This could potentially positively influence the stock's perception among investors, as these firms usually conduct extensive due diligence before committing capital. However, the exercise of accompanying warrants could lead to dilution of existing shares, which is a common concern for shareholders.

Medical Research Analyst

The clinical development of Auxora™ for acute kidney injury (AKI) is of particular interest. AKI is a condition with high unmet medical need, often leading to increased morbidity and mortality. The decision to fund a Phase 2 trial indicates preliminary positive data from earlier studies, suggesting that Auxora™ has potential therapeutic benefits. If successful, the expansion into the AKI market could significantly increase the addressable market for CalciMedica and provide a new treatment option for patients.

It's important to note that clinical trials are inherently risky and the success of Auxora™ in AKI is not guaranteed. Stakeholders should be aware of the biotech industry's high attrition rates for drug candidates. Nevertheless, successful trials could lead to substantial long-term value creation, both in terms of patient impact and company valuation.

Economist

The injection of capital into CalciMedica's operations is a strategic move, not only advancing their clinical programs but also potentially stimulating job creation and economic activity in the biopharmaceutical sector. The decision to begin a Phase 2 trial in the first half of 2024 suggests a forward-looking approach to resource allocation and long-term planning.

Moreover, the involvement of specialized healthcare investors could be indicative of a broader trend where capital is increasingly directed towards innovative medical therapies, especially those targeting conditions with limited treatment options. This could reflect a shift in the economic landscape of healthcare investments, focusing on companies with strong scientific foundations and potential for high-impact therapeutic breakthroughs.

$20.4 million in upfront financing with the potential to receive up to an additional approximately $34.2 million for an aggregate of up to approximately $55 million

Upfront net proceeds to provide funds to expand Auxora™ clinical development to include planned Phase 2 acute kidney injury (AKI) trial expected to begin in 1H 2024

Aggregate net proceeds (assuming exercise of all accompanying warrants) expected to be sufficient to fund CalciMedica through subsequent, potentially pivotal, clinical trials and other work in CalciMedica's acute pancreatitis (AP) and AKI programs

LA JOLLA, Calif., Jan. 22, 2024 /PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced that it has entered into a securities purchase agreement with new and existing investors to raise up to approximately $55 million in gross proceeds that includes initial upfront funding of $20.4 million and up to an additional approximately $34.2 million upon exercise of accompanying warrants.

The financing includes participation from new healthcare-dedicated investors, including an affiliate of Deerfield Management, Soleus Capital, Stonepine Capital Management and Aisling Capital, as well as existing investors Sanderling Ventures and Bering Capital.

"We are excited about this vote of confidence from leading life science investors, which validates the progress we are making in the clinic with Auxora™ targeting acute inflammatory and immunologic diseases," said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. "This financing allows us to initiate clinical trials in AKI, a condition with significant unmet medical need, and brings us closer to our goal of making a meaningful difference in the lives of critically ill patients." 

JonesTrading Institutional Services LLC acted as the sole placement agent for the private placement. H.C. Wainwright & Co. acted as financial advisor to the Company.

Pursuant to terms of the securities purchase agreement, CalciMedica will issue an aggregate of 5,113,812 shares of its common stock (and, in lieu thereof, pre-funded warrants to purchase 351,352 shares of common stock) and accompanying warrants to purchase up to an aggregate of 5,465,164 shares of its common stock (or pre-funded warrants in lieu thereof) at a combined purchase price of $3.70 per share and accompanying warrants (or $4.3915 per share and accompanying warrants for directors, employees or consultants participating in the private placement), in accordance with the "Minimum Price" requirement as defined in the Nasdaq rules. The accompanying warrants consist of two tranches:

• Tranche A warrants to purchase up to 2,732,582 shares of common stock at an exercise price of $5.36 per share for an aggregate of up to approximately $14.7 million are required to be exercised by the earlier of 30 days following the announcement of topline data (expected 1H 2024) from the CalciMedica's Phase 2b CARPO trial of Auxora in AP patients with accompanying systemic inflammatory response syndrome (SIRS) and December 31, 2024.
• Tranche B warrants to purchase up to 2,732,582 shares of common stock at an exercise price of $7.15 per share for an aggregate of up to approximately $19.5 million are required to be exercised by the earlier of 30 days following the announcement of topline data from the planned Phase 2 clinical trial of Auxora in AKI (expected to start in 1H 2024) and December 31, 2026.

The accompanying warrants are only exercisable in cash, except in limited circumstances. In lieu of shares of common stock, certain investors are purchasing pre-funded warrants at a combined purchase price of $3.6999 per pre-funded warrant and accompanying warrants, which equals the purchase price per share of common stock and accompanying warrant, less the $0.0001 per share exercise price of each pre-funded warrant.  The private placement is expected to close in two closings with the initial closing on or about January 23, 2024 and the second closing expected on or about February 5, 2024, in each case, subject to satisfaction of customary closing conditions.

CalciMedica intends to use the upfront net proceeds from the private placement to fund the Company's ongoing and planned Phase 2 clinical trials for Auxora in AP and AKI, respectively. The aggregate net proceeds (assuming exercise of all accompanying warrants) are expected to be sufficient to fund subsequent, potentially pivotal, clinical trials and other work in CalciMedica's AP and AKI programs.

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering, and the securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. CalciMedica has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock purchased in the private placement and shares of common stock underlying the warrants.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica is currently conducting a Phase 2b trial for a planned 216 patients (called CARPO – NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), with topline data expected in the first half of 2024, as well as supporting the ongoing Phase 1/2 CRSPA asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA – NCT04195347), with additional data expected by 2H 2024. CalciMedica plans to initiate a Phase 2 study in acute kidney injury (AKI) in 1H 2024. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.

Forward-Looking Statements
This communication contains forward-looking statements which include, but are not limited to, statements regarding the timing, terms and completion of the proposed private placement; expected gross proceeds from the proposed private placement and any additional gross proceeds that may be received by CalciMedica upon exercise, if any, of the accompanying warrants issued in the private placement; the expected use of proceeds from the proposed private placement; expectations that the aggregate net proceeds (if received) would be sufficient to fund subsequent, potentially pivotal, clinical trials and other work in CalciMedica's AP and AKI programs; the proposed private placement bringing CalciMedica closer to its goal of making a meaningful difference in the lives of critically ill patients; the design and potential benefits of Auxora, including its potential to reduce the severity of AP and AKI; CalciMedica's plans and expected timing for developing its product candidates and potential benefits of its product candidates; CalciMedica's plans and expected timing with respect to its ongoing and planned clinical trials, including the milestones, data announcements, expected enrollment, potential benefits of and any other potential results related thereto. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. CalciMedica's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the impact of fluctuations in global financial markets on CalciMedica's business and the actions it may take in response thereto; CalciMedica's ability to execute its plans and strategies; the ability to obtain and maintain regulatory approval for Auxora; results from clinical trials may not be indicative of results that may be observed in the future; potential safety and other complications from Auxora; the scope progress and expansion of developing and commercializing Auxora; the size and growth of the market therefor and the rate and degree of market acceptance thereof; economic, business, competitive, and/or regulatory factors affecting the business of CalciMedica generally; CalciMedica's ability to protect its intellectual property position; and the impact of government laws and regulations. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" in CalciMedica's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 and elsewhere in CalciMedica's subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can be accessed on CalciMedica's web page at ir.calcimedica.com/financials-filings/sec-filings.

CalciMedica Contact:

Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902

View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-private-placement-of-up-to-approximately-55-million-302040624.html

SOURCE CalciMedica, Inc.

FAQ

What is the purpose of the financing announced by CalciMedica, Inc.?

The financing aims to raise up to $55 million in gross proceeds, with an upfront funding of $20.4 million and potential additional funding of $34.2 million. It will support the expansion of Auxora™ clinical development and subsequent clinical trials in acute pancreatitis (AP) and AKI programs.

Who are the participants in the financing announced by CalciMedica, Inc.?

New and existing investors, including healthcare-dedicated investors such as an affiliate of Deerfield Management, Soleus Capital, Stonepine Capital Management, Aisling Capital, Sanderling Ventures, and Bering Capital, are participating in the financing.

What clinical development will be expanded with the financing announced by CalciMedica, Inc.?

The financing will support the expansion of Auxora™ clinical development, including a planned Phase 2 acute kidney injury (AKI) trial.

What are the expected net proceeds from the financing announced by CalciMedica, Inc.?

The aggregate net proceeds, assuming the exercise of all accompanying warrants, are expected to be sufficient to fund CalciMedica through subsequent, potentially pivotal, clinical trials and other work in acute pancreatitis (AP) and AKI programs.